Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 324, Issue 3, 2008, Pages 992-999

  Siu, Eric C K ^a   Tyndale, Rachel F ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; CYTOCHROME P450 2A5; CYTOCHROME P450 2A6; DESMETHYLSELEGILINE; METHAMPHETAMINE; NICOTINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SELEGILINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; MALE; METABOLIC INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SMOKING CESSATION;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; HUMANS; MALE; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED DBA; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; NICOTINE; SELEGILINE;

EID: 40849119970     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.133900     Document Type: Article

References (39)

1. Balfour DJ (2004) The neurobiology of tobacco dependence: a preclinical perspective on the role of the dopamine projections to the nucleus accumbens. Nicotine Tob Res 6:899-912 [Erratum in Nicotine Tob Res 7:307, 2005].
2. Benetton SA, Fang C, Yang YO, Alok R, Year M, Lin CC, and Yeh LT (2007) P450 phenotyping of the metabolism of selegiline to desmethylselegiline and methamphetamine. Drug Metab Pharmacokinet 22:78-87.
3. Benowitz NL, Jacob P 3rd, Denaro C, and Jenkins R (1991) Stable isotope studies of nicotine kinetics and bioavailability. Clin Pharmacol Ther 49:270-277.
4. Biberman R, Neumann R, Katzir I, and Gerber Y (2003) A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation. Addiction 98:1403-1407.
5. Correia MA and Ortiz de Montellano PR (2005) Inhibition of Cytochrome P450 Enzymes, Kluwer Academic/Plenum, New York.
6. Damaj MI, Siu EC, Sellers EM, Tyndale RF, and Martin BR (2007) Inhibition of nicotine metabolism by methoxysalen: pharmacokinetic and pharmacological studies in mice. J Pharmacol Exp Ther 320:250-257.
7. Dyck LE and Davis BA (2001) Inhibition of rat liver microsomal CYP1A2 and CYP2B1 activity by N-(2-heptyl)-N-methyl-propargylamine and by N-(2-heptyl)-propargylamine. Drug Metab Dispos 29:1156-1161.
8. Fowler JS, MacGregor RR, Wolf AP, Arnett CD, Dewey SL, Schlyer D, Christman D, Logan J, Smith M, Sachs H, et al. (1987) Mapping human brain monoamine oxidase A and B with 11C-labeled suicide inactivators and PET. Science 235:481-485.
9. Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, MacGregor R, Alexoff D, Shea C, Schlyer D, Wolf AP, et al. (1996) Inhibition of monoamine oxidase B in the brains of smokers. Nature 379:733-736.
10. Fredriksson A and Archer T (1995) Synergistic interactions between COMT-/MAO-inhibitors and L-Dopa in MPTP-treated mice. J Neural Transm Gen Sect 102:19-34.
11. George TP, Vessicchio JC, Termine A, Jatlow PI, Kosten TR, and O'Malley SS (2003) A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation. Biol Psychiatry 53:136-143.
12. Gerlach M, Youdim MB, and Riederer P (1996) Pharmacology of selegiline. Neurology 47:S137-S145.
13. Ghanbari F, Rowland-Yeo K, Bloomer JC, Clarke SE, Lennard MS, Tucker GT, and Rostami-Hodjegan A (2006) A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation. Curr Drug Metab 7:315-334.
14. Gilbert DG, Zuo Y, Browning RA, Shaw TM, Rabinovich NE, Gilbert-Johnson AM, and Plath L (2003) Platelet monoamine oxidase B activity changes across 31 days of smoking abstinence. Nicotine Tob Res 5:813-819.
15. Gu DF, Hinks LJ, Morton NE, and Day IN (2000) The use of long PCR to confirm three common alleles at the CYP2A6 locus and the relationship between genotype and smoking habit. Ann Hum Genet 64:383-390.
16. Gu J, Zhang QY, Genter MB, Lipinskas TW, Negishi M, Nebert DW, and Ding X (1998) Purification and characterization of heterologously expressed mouse CYP2A5 and CYP2G1: role in metabolic activation of acetaminophen and 2,6-dichlorobenzonitrile in mouse olfactory mucosal microsomes. J Pharmacol Exp Ther 285:1287-1295.
17. Heinonen EH, Anttila MI, Karnani HL, Nyman LM, Vuorinen JA, Pyykko KA, and Lammintausta RA (1997) Desmethylselegiline, a metabolite of selegiline, is an irreversible inhibitor of monoamine oxidase type B in humans. J Clin Pharmacol 37:602-609.
18. Heinonen EH, Anttila MI, and Lammintausta RA (1994) Pharmacokinetic aspects of L-deprenyl (selegiline) and its metabolites. Clin Pharmacol Ther 56:742-749.
19. Henningfield JE and Keenan RM (1993) Nicotine delivery kinetics and abuse liability. J Consult Clin Psychol 61:743-750.
20. Houtsmuller EJ, Thornton JA, and Stitzer ML (2002) Effects of selegiline (L-deprenyl) during smoking and short-term abstinence. Psychopharmacology (Berl) 163:213-220.
21. Khalil AA, Steyn S, and Castagnoli N Jr (2000) Isolation and characterization of a monoamine oxidase inhibitor from tobacco leaves. Chem Res Toxicol 13:31-35.
22. Laine K, Anttila M, Huupponen R, Maki-Ikola O, and Heinonen E (2000) Multiple-dose pharmacokinetics of selegiline and desmethylselegiline suggest saturable tissue binding. Clin Neuropharmacol 23:22-27.
23. Lévai F, Fejer E, Szeleczky G, Szabo A, Eros-Takacsy T, Hajdu F, Szebeni G, Szatmari I, and Hermecz I (2004) In vitro formation of selegiline-N-oxide as a metabolite of selegiline in human, hamster, mouse, rat, guinea-pig, rabbit and dog. Eur J Drug Metab Pharmacokinet 29:169-178.
24. Lewis A, Miller JH, and Lea RA (2007) Monoamine oxidase and tobacco dependence. Neurotoxicology 28:182-195.
25. Marks MJ, Romm E, Bealer SM, and Collins AC (1985) A test battery for measuring nicotine effects in mice. Pharmacol Biochem Behav 23:325-330.
26. McRobbie H, Lee M, and Juniper Z (2005) Non-nicotine pharmacotherapies for smoking cessation. Respir Med 99:1203-1212.
27. Messina ES, Tyndale RF, and Sellers EM (1997) A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J Pharmacol Exp Ther 282:1608-1614.
28. Murphy SE, Raulinaitis V, and Brown KM (2005) Nicotine 5′-oxidation and methyl oxidation by P450 2A enzymes. Drug Metab Dispos 33:1166-1173.
29. Rahnasto M, Raunio H, Poso A, and Juvonen RO (2003) More potent inhibition of human CYP2A6 than mouse CYP2A5 enzyme activities by derivatives of phenylethylamine and benzaldehyde. Xenobiotica 33:529-539.
30. Schneider LS, Tariot PN, and Goldstein B (1994) Therapy with L-deprenyl (selegiline) and relation to abuse liability. Clin Pharmacol Ther 56:750-756.
31. Sellers EM, Kaplan HL, and Tyndale RF (2000) Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking. Clin Pharmacol Ther 68:35-43.
32. Sellers EM, Ramamoorthy Y, Zeman MV, Djordjevic MV, and Tyndale RF (2003) The effect of methoxsalen on nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)- 1-butanone (NNK) metabolism in vivo. Nicotine Tob Res 5:891-899.
33. Shin HS (1997) Metabolism of selegiline in humans: identification, excretion, and stereochemistry of urine metabolites. Drug Metab Dispos 25:657-662.
34. Siu EC and Tyndale RF (2007) Characterization and comparison of nicotine and cotinine metabolism in vitro and in vivo in DBA/2 and C57BL/6 mice. Mol Pharmacol 71:826-834.
35. Siu EC, Wildenauer DB, and Tyndale RF (2006) Nicotine self-administration in mice is associated with rates of nicotine inactivation by CYP2A5. Psychopharmacology (Berl) 184:401-408.
36. Valoti M, Fusi F, Frosini M, Pessina F, Tipton KF, and Sgaragli GP (2000) Cytochrome P450-dependent N-dealkylation of L-deprenyl in C57BL mouse liver microsomes: effects of in vivo pretreatment with ethanol, phenobarbital, β-naphthoflavone and L-deprenyl. Eur J Pharmacol 391:199-206.
37. Xu C, Rao YS, Xu B, Hoffmann E, Jones J, Sellers EM, and Tyndale RF (2002) An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles. Biochem Biophys Res Commun 290:318-324.
38. Youdim MB (1978) The active centers of monoamine oxidase types "A" and "B": binding with (14C)-clorgyline and (14C)-deprenyl. J Neural Transm 43:199-208.
39. Youdim MB, Edmondson D, and Tipton KF (2006) The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 7:295-309.